ID
42014
Description
Study part: Prior treatment for metastatic breast cancer. A phase III multinational, randomized, single-blind study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2/neu overexpression who have not received prior cytotoxic chemotherapy for metastatic breast cancer. "Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche"
Keywords
Versions (2)
- 5/16/17 5/16/17 -
- 3/15/21 3/15/21 - Dr. rer. medic Philipp Neuhaus
Copyright Holder
Roche
Uploaded on
March 15, 2021
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
PRIOR TREATMENT FOR METASTATIC BREAST CANCER Roche H0650g Breast Cancer
PRIOR TREATMENT FOR METASTATIC BREAST CANCER
- StudyEvent: ODM
Description
HORMONAL THERAPY IN METASTATIC SETTING
Alias
- UMLS CUI-1
- C0279025
- UMLS CUI-2
- C0027627
Similar models
PRIOR TREATMENT FOR METASTATIC BREAST CANCER
- StudyEvent: ODM
C0851346 (UMLS CUI [1,2])
C0027627 (UMLS CUI-2)